Meta AnalysisID 873
痴呆或认知障碍患者色氨酸-犬尿氨酸通路相关代谢物失调的Meta分析
CRD42020159274
1. Do patients with mild cognitive impairment or dementia have higher mean plasma or cerebrospinal fluid levels of tryptophan/kynurenines metabolites compared to controls? 2. Are tryptophan/kynurenines metabolites associ
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 873
- Evidence Id
- 9431
- Core Evidence Id
- 9431
- Source Meta Analysis Id
- 848
- Herb2 Meta Analysis Id
- HBMA000848
- Crd Id
- CRD42020159274
- Title
- Dysregulation of tryptophan-kynurenine pathway associated metabolites in patients with dementia or cognitive impairment: a meta-analysis
- Review Question
- 1. Do patients with mild cognitive impairment or dementia have higher mean plasma or cerebrospinal fluid levels of tryptophan/kynurenines metabolites compared to controls? 2. Are tryptophan/kynurenines metabolites associated with severity of cognitive impairment or dementia stages? 3. Are tryptophan/kynurenines metabolites associated with affective symptoms in mild cognitive impairment or dementia?
- Study Type Included
- Inclusion criteria: - Prospective cohort studies, cross-sectional studies, case-control studies, randomized controlled trials - Studies must measure one or more of the tryptophan-kynurenine metabolite(s): tryptophan, N-formylkynurenine, formyl-anthranilic acid, kynurenine, kynurenic acid, 3-hydroxy-kynurenine, 3-OH-kynurenine, xanthurenic acid 3-hydroxy-anthranilic acid, 3-OH-anthranilic acid, anthranilic acid, cinnabarinic acid, 2-amino-3-carboxymuconic-6-semialdehyde, 2-aminomuconic-6-semialdehyde, picolinic acid, or quinolinic acid. - Studies investigating on patients with a diagnosis of one or more of the following disease(s): dementia (Alzheimer’s disease, vascular dementia, Creutzfeldt-Jakob disease, lewy body dementia, down syndrome, frontotemporal dementia, Huntington’s disease, mixed dementia, normal pressure hydrocephalus, posterior cortical atrophy, Parkinson’s disease, and Korsakoff syndrome) or cognitive impairment (subjective, mild, or vascular). - Studies investigating changes in metabolite levels with normal aging/cognition on healthy participants. - Human participants and human biomaterials (blood, CSF, urine, post-mortem tissues, peripheral blood mononuclear cell, etc.). - Studies investigating either cases vs controls or cases vs cases. - Studies that investigate cognitive and/or affective symptomatology must provide metabolite levels.
- Condition Being Studied
- Dementia, cognitive and affective symptomology, and aging. Dementia is an overall term for diseases and conditions characterized by a decline in memory, language, problem solving and other thinking skills that affect a person’s ability to perform everyday activities. Alzheimer’s disease is the most common type of dementia, but there are many other kinds (e.g. vascular dementia, Creutzfeldt-Jakob disease, lewy body dementia, down syndrome, frontotemporal dementia, Huntington’s disease, mixed dementia, normal pressure hydrocephalus, posterior cortical atrophy, Parkinson’s disease, and Korsakoff syndrome). In addition, aging is the main cause of dementia and patients with dementia have higher chance of developing affective disorders such as depression, apathy and anxiety.
- Participant
- Inclusion: Patients diagnosed with mild cognitive impairment or dementia (as diagnosed using established diagnostic criteria) with or without affective symptoms and cognitively healthy control participants (general population, hospital controls). Exclusion: Patients with affective disorders, but without a diagnosis of mild cognitive impairment or dementia. Also, patients with other types of neurological disorders other than dementia.
- Animal
- Human Disease Modelled
- Intervention
- Tryptophan is a precursor to multiple pathways (e.g. kynurenine, serotonin, melatonin, tryptamine, nicotinamide adenine dinucleotide (NAD), and protein synthesis). Kynurenine pathway is the dominant pathway, accounting for >90% of tryptophan metabolism both in peripheral and central nervous system and have shown contrasting effects both neurotoxic (e.g. quinolinic acid) and neuroprotective (e.g. kynurenic acid) properties in the brain.
- Comparator Control
- No neurological disorder patients (control). Comparison between different stages/severity of dementia (e.g. subjective cognitive impairment, mild cognitive impairment, and Alzheimer’s disease). Comparison between different ages of controls.
- Main Outcome
- Differences in tryptophan-kynurenine pathway associated metabolites in patients with dementia, as compared to neurologically normal controls. Measures of effect Metabolite measurements as performed in human biomaterial(s).
- Outcome Measure
- Additional Outcome
- 1. Differences in tryptophan-kynurenine pathway associated metabolites in different stages of patients with dementia. 2. Differences in metabolite and cognitive/affective scores in patients with dementia and control patients or in different dementia related disease stages. Measures of effect Metabolite measurements as performed in human biomaterial(s).
- Study Method
- Diagnostic, Epidemiologic, Meta-analysis, Prevention, Systematic review
- Keyword
- Cognitive Dysfunction; Dementia; Diagnostic Tests, Routine; Humans; Kynurenine; Tryptophan
- Contact
- Sebastian Köhler [email protected]
- Organisational Affiliation
- School for Mental Health and Neuroscience (MHeNS), Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands. https://www.maastrichtuniversity.nl/
- Funding Source
- Internal funding provided by the School of Mental Health and Neuroscience (MHeNS), Department of Psychiatry and Neuropsychology, Maastricht University
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Netherlands
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-11-25
- Registration Date
- 2020-03-11
- Anticipated Start Date
- 2019-11-06
- Anticipated Completion Date
- 2020-11-06
- Title Cn
- 痴呆或认知障碍患者色氨酸-犬尿氨酸通路相关代谢物失调的Meta分析
- Title En
- Dysregulation of tryptophan-kynurenine pathway associated metabolites in patients with dementia or cognitive impairment: a meta-analysis
- Bilingual Status
- complete